Serum anti-heart and anti-intercalated disk autoantibodies provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis (P=0.04).
Observational (n=270)
Yes
Do serum AHAs and AIDAs serve as diagnostic autoimmune markers in patients with cardiac sarcoidosis?
Serum AHAs and AIDAs may serve as novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis.
p-value: p=0.04
BACKGROUND: Sarcoidosis is an immune-mediated disease. Cardiac involvement, a granulomatous form of myocarditis, is under-recognized and prognostically relevant. Anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in nonsarcoidosis myocarditis forms. OBJECTIVE: The aim was to assess serum AHAs and AIDAs as autoimmune markers in cardiac sarcoidosis. METHODS: = 270). Sarcoidosis patients were recruited in two recruiting tertiary centers in the USA and Italy. AHAs and AIDAs were detected by indirect immunofluorescence on the human myocardium and skeletal muscle. RESULTS: = 0.04). CONCLUSIONS: Serum AHAs and AIDAs provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis.
Caforio et al. (Wed,) conducted a observational in Cardiac sarcoidosis (n=270). Serum AHAs and AIDAs assessment was evaluated on Serum AHAs and AIDAs as autoimmune markers (p=0.04). Serum anti-heart and anti-intercalated disk autoantibodies provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis (P=0.04).